ECCMID

2017 – Farkas A, Unis D, Koo A, Mckinley G, Stavropoulos C, Conceptual framework for the design of individualized anti-infective impregnated bone cement : a voriconazole example

2017 – Farkas A, Villasurda P, Koo A, Sordillo E, Mckinley G, Pharmacokinetic and pharmacodynamic evaluation of vancomycin for the prophylaxis of surgical site infections in morbidly obese patients

2017 – Farkas A, Villasurda P, Koo A, Mckinley G, Central nervous system pharmacodynamics of intraventricular doses of Vancomycin in neurosurgical patients with external ventricular drains

2017 – Farkas A, Villasurda P, Hoffman C, Koo A, Mckinley G, Pharmacodynamic profiling of oritavancin dosing regimens for salvage therapy of vancomycin resistant enterococcus endocarditis: semi-mechanistic modelling of rabbit infection data to support human dosing regimens

2017 – Duttra S, Sanches G C, Roberts J, Daroczi G, Farkas A, Development of an on-line application to support a program aimed to evaluate antimicrobial dosing optimization without therapeutic drug monitoring in critically ill patients in Brazil

2016 – Farkas A, Luque S, Frei O, Roehr A, Grau S, Roberts J, Population pharmacokinetics of linezolid as it applies to therapeutic drug monitoring: a comparison of ten approaches

2015 – Farkas A, Feng Guan L, Villasurda Pp, Dolton M, Roberts J, Comparative evaluation of the predictive performance of three different structural population pharmacokinetic models to predict future voriconazole concentration

2015 – Farkas A, Hoffman C, Zeolla M, Chin N R, Application of drug interaction modelling and Monte Carlo simulation to predict the potential killing effect of combination antimicrobial treatment regimens in humans

2015 – Farkas A, Hoffman C, Zeolla M, Chin N R, Quantitative assessment of the combination of doripenem or tigecycline with amikacin therapy against an isolate of carbapenemase-producing Klebsiella pneumoniae using drug interaction modelling

2015 – Farkas A, Daroczi G, Development of a smart phone application to individualize antibiotic dosing in critically ill patients using Monte Carlo simulations, Bayesian feedback and drug interaction modelling approaches

2014 – Farkas A, Daroczi G, Roberts J, Population Probability of Target Attainment of Colistin at Different Levels of Renal Function Against Pseudomonas aeruginosa and Acinetobacter baumanii in Europe

2014 – Farkas A, Daroczi G, Roberts J, Usage statistics of Individually Designed Optimum Dosing Strategies, a multi-model based online application to individualize antibiotic dosing in critically ill patients

2014 – Farkas A, Wong G, Daroczi G, Lipman J, Roberts J, Population pharmacokinetics of meropenem in critically ill patients: a comparison of eight approaches

2014 – Farkas A, Wong G, Daroczi G, Lipman J, Roberts J, Use of Bayesian Pharmacokinetic Models to Predict Meropenem Concentrations in Critically Ill Patients – Application to Therapeutic Drug Monitoring

2013 – Farkas A, Pharmacodynamic profiling of prolonged infusion of ertapenem in critically ill patients with early-onset ventilator-associated pneumonia through the use of a population pharmacokinetic model and Monte Carlo simulation

2013 – Farkas A; Pulmonary target attainment rates of short andextended infusion meropenem dosing regimens based on simulated epithelial lining fluid levels

2013 – Farkas A, Model-based optimization of daptomycin dosing during high-intensity renal replacement therapy

2013 – Farkas A, Development of a smart-phone application prototype to individualize antibiotic dosing in critically ill patients based on the results of population pharmacokinetic models and Monte Carlo simulation

2013 – Farkas A, Development of ID-ODS, a web based simulation service to help individualize antibiotic dosing in critically ill patients: the doripenem example

2013 – Farkas A, Evaluation of the effects of racial differences on the pharmacodynamics of doripenem in critically ill patients

2013 – Farkas A, Site-specific target attainment rates of meropenem for central nervous system infections and the benefits of extending the infusion time based on celebrospinal fluid levels

2013 – Farkas A, Jodlowsky T, Lee Y, Saunders-Hao P, Avisrur K, Selection of optimal empiric antimicrobial therapy against Pseudomonas aeruginosa in the Greater New York City area

2012 – Farkas A, Population probability of target attainment of daptomycin (DAP) at different levels of renal function against Methicillin Resistant Staphylococcus aureus in European medical centers